NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback